Protection of Ovarian Function in Female Patients With Hodgkin Lymphoma

Randomisierte Phase II Studie Zum Einsatz Von Goserelin Und Oralen Kontrazeptiva Zur Reduktion Ovarieller Toxizitäten während Zytostatischer Primärtherapie Bei Fertilen Patientinnen Mit Hodgkin Lymphom in Fortgeschrittenen Stadien

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01014507

Acronym

PROFE

Enrollment

Registered

2009-11-17

Start date

2004-01-31

Completion date

2009-09-30

Last updated

2012-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hodgkins Lymphoma

Brief summary

This study is designed to test the the protective capacity of Goserelin compared with oral contraceptive

Interventions

DRUG8 cycles BEACOPPesc plus oral contraceptive

DRUG8 cycles BEACOPPesc plus Goserelin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 40 Years

Healthy volunteers

Inclusion criteria

* Advanced stage Hodgkins Lymphoma (histologically proven) * Normal FSH-levels * Written informed consent

Exclusion criteria

* Hodgkins Lymphoma as composite lymphoma * Primary ovarial dysfunction * Age \> 40

Design outcomes

Primary

Measure	Time frame
FSH level 6 month after end of treatment	6 month

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026